{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:29:51Z","timestamp":1787678991925,"version":"build-2784847793"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T00:00:00Z","timestamp":1387411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40257-013-0056-2","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T07:43:13Z","timestamp":1387352593000},"page":"17-36","source":"Crossref","is-referenced-by-count":32,"title":["Oral Therapy for Onychomycosis: An Evidence-Based Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Daniel Coelho","family":"de S\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Botto","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,19]]},"reference":[{"issue":"Pt 1","key":"56_CR1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","volume":"43","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(Pt 1):244\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-4362.1997.00349.x","volume":"36","author":"AK Gupta","year":"1997","unstructured":"Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists\u2019 offices in Ontario, Canada\u2014a multicenter survey of 2001 patients. Int J Dermatol. 1997;36:783\u20137.","journal-title":"Int J Dermatol"},{"key":"56_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1440-0960.1999.00308.x","volume":"40","author":"D Gill","year":"1999","unstructured":"Gill D, Marks R. A review of the epidemiology of tinea unguium in the community. Australas J Dermatol. 1999;40:6\u201313.","journal-title":"Australas J Dermatol"},{"key":"56_CR4","first-page":"11","volume":"34","author":"RK Scher","year":"1998","unstructured":"Scher RK, Coppa LM. Advances in the diagnosis and treatment of onychomycosis. Hosp Med. 1998;34:11\u201320.","journal-title":"Hosp Med"},{"key":"56_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","volume":"11","author":"BE Elewski","year":"1998","unstructured":"Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11:415\u201329.","journal-title":"Clin Microbiol Rev"},{"key":"56_CR6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2133.1995.tb02741.x","volume":"133","author":"H Heikkil\u00e4","year":"1995","unstructured":"Heikkil\u00e4 H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133:699\u2013703.","journal-title":"Br J Dermatol"},{"issue":"11\u201312","key":"56_CR7","first-page":"496","volume":"46","author":"M Dahdah","year":"2008","unstructured":"Dahdah M, Scher R. Onychomycosis\u2014an overview. Mycoses. 2008;46(11\u201312):496\u2013505.","journal-title":"Mycoses"},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","volume":"133","author":"BE Elewski","year":"1997","unstructured":"Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol. 1997;133:1172\u20133.","journal-title":"Arch Dermatol"},{"key":"56_CR9","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(96)90061-4","volume":"35","author":"RK Scher","year":"1996","unstructured":"Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol. 1996;35:S2\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"56_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2007.00109.x","volume":"20","author":"JJ Finch","year":"2007","unstructured":"Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20(1):31\u201346.","journal-title":"Dermatol Ther"},{"key":"56_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(97)80215-0","volume":"36","author":"AK Gupta","year":"1997","unstructured":"Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol. 1997;36:395\u2013402.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR12","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/978-0-387-78665-0_223","volume-title":"Handbook of disease burdens and quality of life measures","author":"A Reich","year":"2010","unstructured":"Reich A, Szepietowski JC. Quality of life in toenail onychomycosis. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York: Springer; 2010. p. 3837\u201350."},{"issue":"Suppl 1","key":"56_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2005.01288.x","volume":"19","author":"R Hay","year":"2005","unstructured":"Hay R. Literature review. Onychomycosis. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):1\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"56_CR14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1529-8019.2012.01551.x","volume":"25","author":"A Shemer","year":"2012","unstructured":"Shemer A. Update: medical treatment of onychomycosis. Dermatol Ther. 2012;25(6):582\u201393.","journal-title":"Dermatol Ther"},{"issue":"6","key":"56_CR15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0378-6323.86475","volume":"77","author":"A Singal","year":"2011","unstructured":"Singal A, Khanna D. Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol. 2011;77(6):659\u201372.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"suppl 1","key":"56_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1468-3083.2005.01284.x","volume":"19","author":"M Lecha","year":"2005","unstructured":"Lecha M, Effendy I, de Chauvin MF, et al. Treatment options\u2014development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(suppl 1):25\u201333.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"56_CR17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1439-0507.2012.02199.x","volume":"55","author":"C Grover","year":"2012","unstructured":"Grover C, Khurana A. An update on treatment of onychomycosis. Mycoses. 2012;55(6):541\u201351.","journal-title":"Mycoses"},{"issue":"3","key":"56_CR18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","volume":"11","author":"BE Elewski","year":"1998","unstructured":"Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415\u201329.","journal-title":"Clin Microbiol Rev"},{"issue":"Pt 3","key":"56_CR19","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0190-9622(98)70481-5","volume":"38","author":"EG Evans","year":"1998","unstructured":"Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol. 1998;38(Pt 3):S32\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"56_CR20","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.2310\/7750.2006.00056","volume":"10","author":"RB Vender","year":"2006","unstructured":"Vender RB, Lynde CW, Poulin Y. Prevalence and epidemiology of onychomycosis. J Cutan Med Surg. 2006;10(Suppl 2):S28\u201333.","journal-title":"J Cutan Med Surg"},{"key":"56_CR21","doi-asserted-by":"crossref","unstructured":"Haneke E. Achilles foot-screening project: background, objectives and design. J Eur Acad Dermatol Venereol. 1999;12(Suppl 1):S2\u20135 (discussion S17).","DOI":"10.1111\/j.1468-3083.1999.tb00908.x"},{"key":"56_CR22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.0933-7407.2003.00933.x","volume":"46","author":"T Burzykowski","year":"2003","unstructured":"Burzykowski T, Molenberghs G, Abeck D, Haneke E, Hay R, Katsambas A, et al. High prevalence of foot diseases in Europe: results of the Achilles Project. Mycoses. 2003;46:496\u2013505.","journal-title":"Mycoses"},{"issue":"Suppl 4","key":"56_CR23","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","volume":"43","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(Suppl 4):S70\u201380.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199243020-00010","volume":"43","author":"JA Balfour","year":"1992","unstructured":"Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drags. 1992;43:259\u201384.","journal-title":"Drags"},{"key":"56_CR25","first-page":"1031","volume":"318","author":"EG Evans","year":"1999","unstructured":"Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. Br J Dermatol. 1999;318:1031\u20135.","journal-title":"Br J Dermatol"},{"issue":"Suppl 39","key":"56_CR26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","volume":"126","author":"NS Ryder","year":"1992","unstructured":"Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2\u20137.","journal-title":"Br J Dermatol"},{"issue":"Suppl 39","key":"56_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2133.1992.tb00009.x","volume":"126","author":"F Baudraz-Rosselet","year":"1992","unstructured":"Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine. Br J Dermatol. 1992;126(Suppl 39):40\u20136.","journal-title":"Br J Dermatol"},{"issue":"Suppl. 39","key":"56_CR28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2133.1992.tb00006.x","volume":"126","author":"A Finlay","year":"1992","unstructured":"Finlay A. Pharmacokinetics of terbinafine in the nail. Br J Dermatol. 1992;126(Suppl. 39):28\u201332.","journal-title":"Br J Dermatol"},{"issue":"Suppl 39","key":"56_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2133.1992.tb00007.x","volume":"126","author":"MJ Goodfield","year":"1992","unstructured":"Goodfield MJ. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol. 1992;126(Suppl 39):33\u20135.","journal-title":"Br J Dermatol"},{"issue":"5 Pt 1","key":"56_CR30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0190-9622(95)91815-9","volume":"33","author":"A Watson","year":"1995","unstructured":"Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995;33(5 Pt 1):775\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1346-8138.1996.tb04009.x","volume":"23","author":"E Alpsoy","year":"1996","unstructured":"Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol. 1996;23:259\u201362.","journal-title":"J Dermatol"},{"issue":"5 Pt 1","key":"56_CR32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0190-9622(97)70111-7","volume":"37","author":"LA Drake","year":"1997","unstructured":"Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37(5 Pt 1):740\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"56_CR33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-4362.1999.00713.x","volume":"38","author":"S Billstein","year":"1999","unstructured":"Billstein S, Kianifard F, Justice A. Terbinafine vs. placebo for onychomycosis in black patients. Int J Dermatol. 1999;38(5):377\u20139.","journal-title":"Int J Dermatol"},{"issue":"2","key":"56_CR34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2133.2002.04606.x","volume":"146","author":"B Farkas","year":"2002","unstructured":"Farkas B, Paul C, Dobozy A, et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol. 2002;146(2):254\u201360.","journal-title":"Br J Dermatol"},{"issue":"4","key":"56_CR35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jaad.2005.04.055","volume":"53","author":"EM Warshaw","year":"2005","unstructured":"Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2005;53(4):578\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"56_CR36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1439-0507.2008.01531.x","volume":"52","author":"Y Takahata","year":"2009","unstructured":"Takahata Y, Hiruma M, Shiraki Y, et al. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500\u00a0mg day for a week). Mycoses. 2009;52(1):72\u20136.","journal-title":"Mycoses"},{"issue":"2 Pt 1","key":"56_CR37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0190-9622(96)90327-8","volume":"35","author":"RR Assaf","year":"1996","unstructured":"Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol. 1996;35(2 Pt 1):216\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6 Pt 2","key":"56_CR38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0190-9622(98)70490-6","volume":"38","author":"RK Scher","year":"1998","unstructured":"Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450\u00a0mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):77\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"6 Pt 2","key":"56_CR39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0190-9622(98)70492-X","volume":"38","author":"MR Ling","year":"1998","unstructured":"Ling MR, Swinyer LJ, Jarratt MT, et al. Once-weekly fluconazole (450\u00a0mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):95\u2013102.","journal-title":"J Am Acad Dermatol"},{"issue":"6 Pt 2","key":"56_CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0190-9622(98)70491-8","volume":"38","author":"L Drake","year":"1998","unstructured":"Drake L, Babel D, Stewart DM, et al. Once-weekly fluconazole (150, 300, or 450\u00a0mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38(6 Pt 2):87\u201394.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0190-9622(98)70494-3","volume":"38","author":"RC Savin","year":"1998","unstructured":"Savin RC, Drake L, Babel D, et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450\u00a0mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38:110\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"56_CR42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7883\/yoken.JJID.2004.260","volume":"57","author":"X Chen","year":"2004","unstructured":"Chen X, Hiruma M, Shiraki Y, et al. Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. Jpn J Infect Dis. 2004;57(6):260\u20133.","journal-title":"Jpn J Infect Dis"},{"issue":"1","key":"56_CR43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0190-9622(96)90519-8","volume":"35","author":"R Odom","year":"1996","unstructured":"Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol. 1996;35(1):110\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"56_CR44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0190-9622(97)70286-X","volume":"36","author":"RB Odom","year":"1997","unstructured":"Odom RB, Aly R, Scher RK, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol. 1997;36(2 Pt 1):231\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"56_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0190-9622(97)70275-5","volume":"36","author":"PR Doncker De","year":"1997","unstructured":"De Doncker PR, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol. 1997;36(2 Pt 1):173\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1\u20132","key":"56_CR46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1439-0507.1999.00404.x","volume":"42","author":"J Chen","year":"1999","unstructured":"Chen J, Liao W, Wen H, et al. A comparison among four regimens of itraconazole treatment in onychomycosis. Mycoses. 1999;42(1\u20132):93\u20136.","journal-title":"Mycoses"},{"issue":"3\u20134","key":"56_CR47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1439-0507.2001.00628.x","volume":"44","author":"M Hiruma","year":"2001","unstructured":"Hiruma M, Matsushita A, Kobayashi M, et al. One week pulse therapy with itraconazole (200\u00a0mg day\u22121) for onychomycosis. Evaluation of treatment results according to patient background. Mycoses. 2001;44(3\u20134):87\u201393.","journal-title":"Mycoses"},{"issue":"2","key":"56_CR48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1468-3083.2001.00206.x","volume":"15","author":"AK Gupta","year":"2001","unstructured":"Gupta AK, De Doncker P, Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol. 2001;15(2):112\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"56_CR49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/09546630600621953","volume":"17","author":"S Avner","year":"2006","unstructured":"Avner S, Nir N, Baruch K, et al. Two novel itraconazole pulse therapies for onychomycosis: a 2-year follow-up. J Dermatol Treat. 2006;17(2):117\u201320.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"56_CR50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2133.2000.03247.x","volume":"142","author":"V Havu","year":"2000","unstructured":"Havu V, Heikkil\u00e4 H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol. 2000;142(1):97\u2013102.","journal-title":"Br J Dermatol"},{"issue":"1","key":"56_CR51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09546630252775171","volume":"13","author":"E Arca","year":"2002","unstructured":"Arca E, Ta\u015ftan HB, Akar A, et al. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatol Treat. 2002;13(1):3\u20139.","journal-title":"J Dermatol Treat"},{"issue":"7010","key":"56_CR52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/bmj.311.7010.919","volume":"311","author":"M Br\u00e4utigam","year":"1995","unstructured":"Br\u00e4utigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ. 1995;311(7010):919\u201322.","journal-title":"BMJ"},{"issue":"4","key":"56_CR53","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0190-9622(96)80057-0","volume":"34","author":"A Tosti","year":"1996","unstructured":"Tosti A, Piraccini BM, Stinchi C, et al. Terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol. 1996;34(4):595\u2013600.","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 3","key":"56_CR54","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0190-9622(98)70486-4","volume":"38","author":"M Backer De","year":"1998","unstructured":"De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250\u00a0mg\/day versus itraconazole 200\u00a0mg\/day. J Am Acad Dermatol. 1998;38(5 Pt 3):S57\u201363.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 56","key":"56_CR55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","volume":"141","author":"B Sigurgeirsson","year":"1999","unstructured":"Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis. Br J Dermatol. 1999;141(Suppl 56):5\u201314.","journal-title":"Br J Dermatol"},{"issue":"5","key":"56_CR56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1046\/j.1468-3083.2000.00049.x","volume":"14","author":"S Bahadir","year":"2000","unstructured":"Bahadir S, Inal\u00f6z HS, Alpay K, et al. Continuous terbinafine or pulse itraconazole: a comparative study on onychomycosis. J Eur Acad Dermatol Venereol. 2000;14(5):422\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"56_CR57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/09546630050517298","volume":"11","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Konnikov N, Lynde CW. Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. J Dermatol Treat. 2000;11:151\u20134.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"56_CR58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1067\/mjd.2001.110644","volume":"44","author":"AK Gupta","year":"2001","unstructured":"Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44(3):485\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"56_CR59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1365-2133.2002.04639.x","volume":"146","author":"H Heikkil\u00e4","year":"2002","unstructured":"Heikkil\u00e4 H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 2002;146(2):250\u20133.","journal-title":"Br J Dermatol"},{"key":"56_CR60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archderm.138.3.353","volume":"138","author":"B Sigurgeirsson","year":"2002","unstructured":"Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353\u20137.","journal-title":"Arch Dermatol"},{"issue":"9","key":"56_CR61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-4632.2004.02117.x","volume":"44","author":"EM Warshaw","year":"2005","unstructured":"Warshaw EM, Nelson D, Carver SM, et al. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol. 2005;44(9):785\u20138.","journal-title":"Int J Dermatol"},{"issue":"4","key":"56_CR62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0378-6323.16619","volume":"71","author":"M Mishra","year":"2005","unstructured":"Mishra M, Panda P, Tripathy S, et al. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2005;71(4):262\u20136.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"10","key":"56_CR63","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1468-3083.2006.01698.x","volume":"20","author":"AK Gupta","year":"2006","unstructured":"Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol. 2006;20(10):1188\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"56_CR64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1468-3083.2008.03036.x","volume":"23","author":"AK Gupta","year":"2009","unstructured":"Gupta AK, Lynch LE, Kogan N, et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2009;23(3):256\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"56_CR65","first-page":"411","volume":"62","author":"B Piraccini","year":"2010","unstructured":"Piraccini B, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. Dermatology. 2010;62:411\u20134.","journal-title":"Dermatology"},{"issue":"5","key":"56_CR66","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/AAC.01616-09","volume":"54","author":"G Krishna","year":"2010","unstructured":"Krishna G, Beresford E, Ma L, et al. Skin concentrations and pharmacokinetics of posaconazole after oral administration. Antimicrob Agents Chemother. 2010;54(5):1807\u201310.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"56_CR67","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2133.2011.10660.x","volume":"166","author":"B Elewski","year":"2012","unstructured":"Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389\u201398.","journal-title":"Br J Dermatol"},{"issue":"1","key":"56_CR68","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0190-9622(95)90187-6","volume":"32","author":"E Haneke","year":"1995","unstructured":"Haneke E, Tausch I, Br\u00e4utigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. J Am Acad Dermatol. 1995;32(1):72\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"56_CR69","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/0190-9622(95)91454-4","volume":"32","author":"J Faergemann","year":"1995","unstructured":"Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32(5 Pt 1):750\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"56_CR70","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archderm.1995.01690200057011","volume":"131","author":"H Hofmann","year":"1995","unstructured":"Hofmann H, Br\u00e4utigam M, Weidinger G, et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol. 1995;131(8):919\u201322.","journal-title":"Arch Dermatol"},{"issue":"2","key":"56_CR71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jac\/29.2.195","volume":"29","author":"T Piepponen","year":"1992","unstructured":"Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother. 1992;29(2):195\u2013205.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"56_CR72","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1128\/AAC.37.10.2064","volume":"37","author":"HC Korting","year":"1993","unstructured":"Korting HC, Sch\u00e4fer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother. 1993;37(10):2064\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"56_CR73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000051643","volume":"202","author":"AK Gupta","year":"2001","unstructured":"Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology. 2001;202:235\u20138.","journal-title":"Dermatology"},{"key":"56_CR74","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.1997.03890460029004","volume":"133","author":"M Hall","year":"1997","unstructured":"Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133:1213\u20139.","journal-title":"Arch Dermatol"},{"key":"56_CR75","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10227-001-0048-3","volume":"6","author":"AK Gupta","year":"2002","unstructured":"Gupta AK, Chwetzoff E, Del Rosso F, et al. Hepatic safety of itraconazole. J Cutan Med Surg. 2002;6:210\u20133.","journal-title":"J Cutan Med Surg"},{"key":"56_CR76","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2125.1999.00095.x","volume":"48","author":"LA Garcia-Rodriguez","year":"1999","unstructured":"Garcia-Rodriguez LA, Castellsague AD, Perez-Gutthann S, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999;48:847\u201352.","journal-title":"Br J Clin Pharmacol"},{"key":"56_CR77","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-5945-2-14","volume":"2","author":"J Castellsague","year":"2002","unstructured":"Castellsague J, Garcia-Rodriguez LA, Duque A, et al. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol. 2002;2:14.","journal-title":"BMC Dermatol"},{"key":"56_CR78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200022010-00004","volume":"22","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 2000;22:33\u201352.","journal-title":"Drug Saf"},{"key":"56_CR79","first-page":"48","volume":"42","author":"JQ Rosso Del","year":"1999","unstructured":"Del Rosso JQ, Gupta AK, Conte ET. How to recognize and manage adverse reactions to oral antifungals. Skin Aging. 1999;42:48\u201356.","journal-title":"Skin Aging"},{"key":"56_CR80","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.1997.03890460029004","volume":"133","author":"M Hall","year":"1997","unstructured":"Hall M, Monka C, Krupp R, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25, 884 patients. Arch Dermatol. 1997;133:1213\u20139.","journal-title":"Arch Dermatol"},{"key":"56_CR81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1996.tb00049.x","volume":"42","author":"DP O\u2019Sullivan","year":"1996","unstructured":"O\u2019Sullivan DP, Needham CA, Bangs A, et al. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol. 1996;42:559\u201365.","journal-title":"Br J Clin Pharmacol"},{"key":"56_CR82","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0190-9622(94)70112-1","volume":"30","author":"AK Gupta","year":"1994","unstructured":"Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview, part II. J Am Acad Dermatol. 1994;30:911\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR83","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0190-9622(95)90075-6","volume":"32","author":"BE Elewski","year":"1995","unstructured":"Elewski BE. Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol. 1995;32:500\u20131.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archderm.1972.01620120032006","volume":"106","author":"WL Epstein","year":"1972","unstructured":"Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in the stratum corneum: study after oral administration in man. Arch Dermatol. 1972;106:344\u20138.","journal-title":"Arch Dermatol"},{"key":"56_CR85","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cpm.2004.05.003","volume":"21","author":"JA Wenig","year":"2004","unstructured":"Wenig JA. The systemic treatment of onychomycosis. Clin Podiatr Med Surg. 2004;21:579\u201389.","journal-title":"Clin Podiatr Med Surg"},{"issue":"1","key":"56_CR86","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0190-9622(08)81835-X","volume":"29","author":"W Meinhof","year":"1993","unstructured":"Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol. 1993;29(1):S39.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"56_CR87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.510250119","volume":"25","author":"RN Chien","year":"1997","unstructured":"Chien RN, Yang LJ, Lin PY, et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology. 1997;25(1):103\u20137.","journal-title":"Hepatology"},{"key":"56_CR88","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0190-9622(91)70214-M","volume":"25","author":"T Knight","year":"1991","unstructured":"Knight T, Shokuma C, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol. 1991;25:398\u2013400.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR89","volume-title":"Hepatic reactions during ketoconazole treatment: a 1-year update","author":"PAJ Janssen","year":"1983","unstructured":"Janssen PAJ, Cauwenbergh G, Symoens J. Hepatic reactions during ketoconazole treatment: a 1-year update. Beerse: Janssen Pharmaceutica; 1983."},{"issue":"6","key":"56_CR90","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archpedi.154.6.614","volume":"154","author":"PH Huang","year":"2000","unstructured":"Huang PH, Paller AS. Itraconazole pulse therapy for dermatophyte onychomycosis in children. Arch Pediatr Adolesc Med. 2000;154(6):614\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"12","key":"56_CR91","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1046\/j.1440-1746.2003.02852.x","volume":"18","author":"TH Kim","year":"2003","unstructured":"Kim TH, Kim BH, Kim YW, et al. Liver cirrhosis developed after ketoconazole-induced acute hepatic injury. J Gastroenterol Hepatol. 2003;18(12):1426\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"56_CR92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0168-8278(86)80495-0","volume":"3","author":"BH Stricker","year":"1986","unstructured":"Stricker BH, Block APR, Bronkhorst FB, et al. Ketoconazole associated hepatic injury. J Hepatol. 1986;3:399\u2013406.","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"56_CR93","first-page":"S50","volume":"29","author":"RJ Hay","year":"1993","unstructured":"Hay RJ. Risk\/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol. 1993;29(1 Suppl):S50\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR94","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/09546639209088703","volume":"3","author":"K Kuokkanen","year":"1993","unstructured":"Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat. 1993;3:115\u20137.","journal-title":"J Dermatol Treat"},{"key":"56_CR95","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/00007611-199512000-00006","volume":"88","author":"SW Smith","year":"1995","unstructured":"Smith SW, Sealy DP, Schneider E, et al. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J. 1995;88:1217\u201320.","journal-title":"South Med J"},{"key":"56_CR96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archderm.132.1.34","volume":"132","author":"P Doncker De","year":"1996","unstructured":"De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996;132:34\u201341.","journal-title":"Arch Dermatol"},{"issue":"6","key":"56_CR97","first-page":"326","volume":"5","author":"R Alcantara","year":"1988","unstructured":"Alcantara R, Garibay JM. Itraconazole therapy in dermatomycoses and vaginal candidiasis: effects and adverse effects profile in a large multi-center study. Adv Ther. 1988;5(6):326\u201334.","journal-title":"Adv Ther"},{"key":"56_CR98","first-page":"373","volume":"8","author":"R Suhonen","year":"1997","unstructured":"Suhonen R, Neuvonen PJ. The tolerability profile of terbinafine. Rev Contemp Pharmacother. 1997;8:373\u201386.","journal-title":"Rev Contemp Pharmacother"},{"issue":"1","key":"56_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjopharm.2005.12.012","volume":"4","author":"A Tavakkol","year":"2006","unstructured":"Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in Onychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother. 2006;4(1):1\u201313.","journal-title":"Am J Geriatr Pharmacother"},{"key":"56_CR100","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.1997.03890460029004","volume":"133","author":"M Hall","year":"1997","unstructured":"Hall M, Monka C, Krupp R, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25, 884 patients. Arch Dermatol. 1997;133:1213\u20139.","journal-title":"Arch Dermatol"},{"key":"56_CR101","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1996.tb00049.x","volume":"42","author":"DP O\u2019Sullivan","year":"1996","unstructured":"O\u2019Sullivan DP, Needham CA, Bangs A, et al. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol. 1996;42:559\u201365.","journal-title":"Br J Clin Pharmacol"},{"key":"56_CR102","first-page":"522","volume":"4","author":"BHC Stricker","year":"1995","unstructured":"Stricker BHC, Van Riemsdijk MM, Stunkenboom MCJM, et al. Taste loss to terbinafine: a case\u2013control study of potential risk factors [abstract]. Pharmacoepidemiol Drug Saf. 1995;4:522.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"56_CR103","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00042737-200109000-00021","volume":"13","author":"WM Chambers","year":"2001","unstructured":"Chambers WM, Millar A, Jain S, et al. Terbinafine induced hepatic dysfunction. Eur J Gastroenterol Hepatol. 2001;13:1115\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl 43","key":"56_CR104","first-page":"32","volume":"130","author":"SR Arikian","year":"1994","unstructured":"Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group. Br J Dermatol. 1994;130(Suppl 43):32\u20134.","journal-title":"Br J Dermatol"},{"key":"56_CR105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0149-2918(96)80225-6","volume":"18","author":"A Marchetti","year":"1996","unstructured":"Marchetti A, Piech CT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a U.S. model. Clin Ther. 1996;18:757\u201377.","journal-title":"Clin Ther"},{"issue":"Suppl 43","key":"56_CR106","first-page":"35","volume":"130","author":"TR Einarson","year":"1994","unstructured":"Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol. 1994;130(Suppl 43):35\u201344.","journal-title":"Br J Dermatol"},{"key":"56_CR107","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7547\/0960038","volume":"96","author":"EM Warshaw","year":"2006","unstructured":"Warshaw EM. Evaluating costs for onychomycosis treatments: a practitioner\u2019s perspective. J Am Podiatr Med Assoc. 2006;96:38\u201352.","journal-title":"J Am Podiatr Med Assoc"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-013-0056-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0056-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:43:31Z","timestamp":1716324211000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-013-0056-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,19]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s40257-013-0056-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,19]]}}}